Indaptus Therapeutics Inc Down 4.85% To $2.55 After Earnings Beat

Indaptus Therapeutics Inc (INDP) said after close Monday that it lost $0.47 per share in quarter three 2023. The company reported $0.00 in revenue

In the same quarter a year ago, the company lost $0.42 per share on revenue of $0.00.

The stock is down 4.85% to $2.55 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Indaptus Therapeutics Inc a Bearish Sentiment Rank from InvestorsObserver.

Indaptus Therapeutics Inc has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 89, putting Indaptus Therapeutics Inc in the top 25% of stocks. The firm was recently trading at a 52-week high of $4.08 on September 19, 2023 and set a 52-week low on December 28, 2022 at $1.25.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.